Palatin Technologies (NYSE:PTN) Receives New Coverage from Analysts at began coverage on shares of Palatin Technologies (NYSE:PTNGet Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Shares of NYSE:PTN opened at $0.45 on Tuesday. The stock has a market capitalization of $104.26 million, a P/E ratio of -3.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.63 and a current ratio of 3.71. Palatin Technologies has a 52 week low of $0.33 and a 52 week high of $0.96. The firm has a fifty day simple moving average of $0.42.

Palatin Technologies Company Profile (Get Rating)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

See Also

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.